Amarin soars on FDA 2nd look at ANCHOR SPA appeal
This article was originally published in Scrip
Executive Summary
Generally a delay of an FDA decision has investors jittery, but not on the 20 December news from Amarin in which US regulators were not going to act on the company's supplemental new drug application (sNDA) to expand the labeling for its fish oil pill Vascepa (icosapent ethyl).